oral glp-1 drugs in development Lesson: Semaglutide: A New Receptor Agonist Product for the Treatment of Type 2 Diabetes GLP-1 Market Industry Trends and

GLP-1 receptor agonists and DPP4-inhibitor direct the T2DM therapies

NLRP3, NOD-, LRR-, and Pyrin Domain-Containing Protein 3

10.1007/s00404-022-06700-3

in patients with T2DM (38) found that continuous GLP-1 administration via a subcutaneous pump to raise serum GLP-1 levels from a mean of 9.7 pM at baseline to 282 pM over 6 weeks significantly reduced plasma glucose concentrations, improved glycated hemoglobin, and enhanced insulin sensitivity and -cell function compared to placebo, with no significant limiting side effects reported

Yes, inform your GP about any current or previous anxiety disorders and other mental health conditions before starting GLP-1 treatment

Compounded Medication Notice